We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BÜHLMANN LABS

BÜHLMANN designs, develops, manufactures and sells medical diagnostic products and kits (IVD or RUO) in the areas of ... read more Featured Products: More products

Download Mobile App




Test Kit Launched for Crohn’s and Ulcerative Colitis

By LabMedica International staff writers
Posted on 07 May 2015
Print article
Image: The CALEX Valve tube is applied onto the cassette and a precise amount of extract is released by turning the throttle. After a few seconds, when the membrane strip of the cassette gets visibly soaked, the throttle is closed (Photo courtesy of BÜHLMANN).
Image: The CALEX Valve tube is applied onto the cassette and a precise amount of extract is released by turning the throttle. After a few seconds, when the membrane strip of the cassette gets visibly soaked, the throttle is closed (Photo courtesy of BÜHLMANN).
The first in vitro diagnostic test to measure the fecal inflammation marker calprotectin at home has been launched allowing people to self-test for gastrointestinal inflammation that may including the inflammatory bowel diseases Crohn’s and ulcerative colitis.

Inflammatory bowel disease refers to chronic inflammation of all or a portion of the digestive tract. Crohn’s disease is a chronic gastrointestinal tract inflammatory condition that can affect any region of the gastrointestinal tract and ulcerative colitis is a chronic large intestinal disease.

Calprotectin is a fecal-based biomarker that can be used to measure gastrointestinal inflammation. Scientists have found that it corresponds with gastrointestinal damage and with measurements made using endoscopy in both Crohn’s disease and ulcerative colitis. It is believed to be a better biomarker than those measured using blood tests.

BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) has launched the testing kit that combines a stool extraction device called CALEX, a calprotectin test strip and IBDoc smart phone app. Individuals with these potential inflammatory bowel diseases will no longer need to bring stool samples to a clinic or laboratory for testing. Patients are able to read the test result via an image and communicate with healthcare providers using the internet, rather than going to a medical office. A web portal is available and the patient can monitor the test results continuously. The company also assures a high level of security and confidentiality is in place. The test kit is Conformité Européene (CE)-marked.

Thomas Hafen, PhD, the CEO of BÜHLMANN, said, “IBDoc is a milestone for patients, but also a milestone in the still young history of smart phone based clinical applications. Never before has such a sophisticated biologic test system been brought to patients’ homes.” Christian Reinhard, PhD, the company product manager said, “The feedback from enrolled patients so far is phenomenal. Patients are so motivated and they really like to be in charge and at the same time communicating with their nurse or physician.”

Related Links:
BÜHLMANN Laboratories AG


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.